Already there is one such phase III clinical trial success that has led to a marketed approval, i.e., the use of ipilimumab, the CTLA‐4 targeting antibody, for the treatment of postsurgical adjuvant high‐risk melanoma patients (Barker, 2018; Eggermont et al,2018a, 2018b; Helmink et al,2018). Here, CTLA4 is linked to melanoma.